Cardinal Health reported Q1 FY27 revenue of $67.5 billion, +5% YoY, and raised its FY27 non-GAAP EPS guidance to $12.80–$13.00. The company completed a $500 million share repurchase, reaffirmed growth drivers, and disclosed a planned AdaptHealth Diabetes Health acquisition in Q3 FY27 alongside a Lilly-backed real-world evidence study (INSIGHT-IBD). These moves signal improved visibility and potential for multiple expansion amid a favorable pricing backdrop outside tariffs.
Cardinal Health is set to report Q1 results with EPS of $2.94 and revenue near $66.5B. Management reaffirmed FY27 adjusted EPS guidance above estimates, supporting a positive sentiment as several analysts raise targets. The stock advanced about 3.6% ahead of the print, signaling optimism.
Cardinal Health issued a stronger FY2027 profit outlook, topping Q4 profit estimates as demand for specialty drugs remains resilient. The beat signals durable earnings power, potential margin expansion, and improved cash flow visibility. If sustained, CAH could see multiple expansion and analyst upgrades over the next 12-24 months, lifting the stock on a longer runway.
Cardinal Health posted a mixed Q4, with revenue up 6% and profits helped by a one-time tariff refund. The company issued fiscal 2027 EPS guidance above consensus, driven by solid specialty drug demand. Investors should focus on whether this earnings trajectory sustains beyond the non-recurring tariff tailwind and how the mix affects margins.
Cardinal Health has increased its profit forecast for 2026, citing strong demand for specialty and branded medicines in its pharmaceuticals division. This positive outlook indicates potential growth and improved financial performance, which could enhance investor confidence and market valuations.
Cardinal Health reported strong fiscal second-quarter results, with a 19% revenue increase to $65.6 billion and an elevated non-GAAP EPS guidance of $10.15-$10.35 for FY 2026, fueled by demand for specialty medicine. This positive performance indicates a strengthening position in the healthcare distribution sector and may boost investor confidence.
